Detailed information

Notice

The information is provided in the language in which it was submitted by the researcher.

Project title:
Characterizing and targeting lipocalin-type prostaglandin D2 synthase in osteoarthritis
Principal investigator(s):
Fahmi, Hassan
Co-investigator(s):
Martel-Pelletier, Johanne; Pelletier, Jean-Pierre
Supervisors:
N/A
Institution paid:
Centre hospitalier de l'Université de Montréal (CHUM)
Research institution:
Centre hospitalier de l'Université de Montréal (CHUM)
Department:
Medicine
Program:
Project Grant
Competition (year/month):
202010
Assigned peer review committee:
Clinical Investigation - B: Arthritis, Bone, Skin and Cartilage
Primary institute:
Musculoskeletal Health and Arthritis
Primary theme:
Biomedical
Term (yrs/mths):
3 yrs 0 mth
CIHR contribution:
Contributors:
Amount:
$451,349
Equipment:
$0
External funding partner(s):
Partner Name:
N/A
Amount:
N/A
Equipment:
N/A
External applicant partner(s):
Partner Name:
N/A
Amount:
N/A
Equipment:
N/A
External in-kind partner(s):
Partner Name:
N/A
Amount:
N/A
Equipment:
N/A
Keywords:
Cartilage; Dp1; L-Pgds; Osteoarthritis; Pgd2
Abstract/Summary:
OA is the most common form of arthritis and a leading cause of disability in Canada and worldwide. It has a large impact on the patient's quality of life, constitutes a significant socio-economic burden, and there is currently no effective treatment. Therefore, the need to develop an effective therapeutic strategy is an urgent necessity. The overarching goal of our studies is to improve our understanding of the molecular mechanisms underlying the pathogenesis of osteoarthritis with the ultimate goal of developing more effective treatments. Our recent studies strongly suggest that the enzyme, lipocalin-type prostaglandin D synthase (L-PGDS) has protective properties in osteoarthritis. In this project, we will use human tissues and a clinically relevant animal model of OA to define the functions and mode of action of L-PGDS in OA. These studies will improve our understanding of the pathogenesis of OA and may be helpful in developing novel efficacious anti-osteoarthritis therapeutic strategies.
Version:
20231215.2